Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer​

ZHANG Ranran; ZHANG Yuxi; GAO Shengnan; FENG Bing; GAO Ning; LIU Guoqiang

doi:10.6039/j.issn.1001-0408.2025.16.12

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer

更新时间：2025-09-25

- Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 16, Pages: 2024-2029(2025)
- 作者机构：
  
  1.河北医科大学第三医院临床药学部，石家庄　050051
  2.河北省药物与卫生技术综合评估学会，石家庄　050051
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.16.12
  CLC： R956
- Received：19 January 2025，
  
  Revised：2025-07-31，
  
  Accepted：11 August 2025，
  
  Published：30 August 2025
- 稿件说明：
移动端阅览
张冉冉,张羽曦,高胜男,等.芦康沙妥珠单抗对比单药化疗用于转移性三阴性乳腺癌二线及后线治疗的成本-效果分析[J].中国药房,2025,36(16):2024-2029.

ZHANG Ranran,ZHANG Yuxi,GAO Shengnan,et al.Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer[J].ZHONGGUO YAOFANG,2025,36(16):2024-2029.
张冉冉,张羽曦,高胜男,等.芦康沙妥珠单抗对比单药化疗用于转移性三阴性乳腺癌二线及后线治疗的成本-效果分析[J].中国药房,2025,36(16):2024-2029. DOI： 10.6039/j.issn.1001-0408.2025.16.12.

ZHANG Ranran,ZHANG Yuxi,GAO Shengnan,et al.Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer[J].ZHONGGUO YAOFANG,2025,36(16):2024-2029. DOI： 10.6039/j.issn.1001-0408.2025.16.12.

摘要

目的

从我国卫生体系角度出发，评估芦康沙妥珠单抗（ST）对比医生选择的化疗方案（TPC）用于转移性三阴性乳腺癌（mTNBC）二线及后线治疗的经济性。

方法

基于OptiTROP-Breast01研究，根据mTNBC疾病发展过程构建分区生存模型，设置循环周期为4周，模拟时限为10年，贴现率为5%。以质量调整生命年（QALY）和总成本作为产出指标，计算ST方案相对于TPC用于mTNBC二线及后线治疗的增量成本-效果比（ICER），利用敏感性分析验证基础分析结果的稳健性。

结果

在以3倍我国2024年人均国内生产总值（GDP）为意愿支付阈值（287 247元/QALY）的前提下，使用ST方案的患者在获得增量效用（0.42 QALY）的同时也需要支付更多成本，ICER为205 562.07元/QALY，低于意愿支付阈值，表明ST方案相对于TPC更具经济性。单因素敏感性分析结果显示，无进展生存期状态健康效用值和ST成本对ICER值影响较大。概率敏感性分析和情况分析结果表明基础分析结果稳健。

结论

从我国卫生体系角度出发，以3倍我国人均GDP为意愿支付阈值，ST方案相对于TPC用于我国mTNBC患者二线及以后线治疗更具经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of sacituzumab tirumotecan （ST） versus chemotherapy treatment physician’s choice （TPC） as second-line and later-line treatment for metastatic triple-negative breast cancer （mTNBC） from the perspective of China’s healthcare system.

METHODS

A partitioned survival model was constructed based on the OptiTROP-Breast 01 trial， with a cycle length of 4 weeks and a time horizon of 10 years， applying a 5% discount rate. Quality adjusted life year （QALY） and costs were used as outcome measures， and the incremental cost-effectiveness ratio （ICER） of ST versus TPC for second-line and later-line treatment of mTNBC was calculated. Sensitivity analyses were conducted to validate the robustness of the base-case results.

RESULTS

At a willingness-to-pay threshold （WTP） of 3 times China’s 2024 per capita gross domestic product （GDP）（287 247 yuan/QALY）， patients receiving ST gained incremental utility （0.42 QALY） at a higher cost， yielding an ICER of 205 562.07 yuan/QALY， which was lower than WTP， indicating that ST was more cost-effective compared to TPC. One-way sensitivity analysis revealed that key factors influencing the ICER included the utility value of progression-free survival and the price of ST. Probabilistic sensitivity analysis and scenario analysis showed that the base-case results were robust.

CONCLUSIONS

From the perspective of China’s healthcare system， at a WTP of 3 times China’s per capita GDP， ST is more cost-effective than TPC as second-line and later-line treatment for mTNBC.

关键词

Keywords

references

BRAY F ， LAVERSANNE M ， SUNG H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

PATEL G ， PRINCE A ， HARRIES M . Advanced triple-negative breast cancer [J ] . Semin Oncol Nurs ， 2024 ， 40 （ 1 ）： 151548 .

LEON-FERRE R A ， GOETZ M P . Advances in systemic therapies for triple negative breast cancer [J ] . BMJ ， 2023 ， 381 ： e071674 .

KAZMI S ， CHATTERJEE D ， RAJU D ， et al . Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin，gemcitabine，or capecitabine [J ] . Breast Cancer Res Treat ， 2020 ， 184 （ 2 ）： 559 - 565 .

O’SHAUGHNESSY J ， PUNIE K ， OLIVEIRA M ， et al . Assessment of sacituzumab govitecan（SG）versus treatment of physician’s choice（TPC） cohort by agent in the phase 3 ASCENT study of patients（Pts）with metastatic triple-negative breast cancer（mTNBC） [J ] . J Clin Oncol ， 2021 ， 39 （ Suppl. 15 ）： 1077 .

MODI S N ， JACOT W ， YAMASHITA T ， et al . Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [J ] . N Engl J Med ， 2022 ， 387 （ 1 ）： 9 - 20 .

SELIGSON J M ， PATRON A M ， BERGER M J ， et al . Sacituzumab govitecan-hziy：an antibody-drug conjugate for the treatment of refractory，metastatic，triple-negative breast cancer [J ] . Ann Pharmacother ， 2021 ， 55 （ 7 ）： 921 - 931 .

BARDIA A ， HURVITZ S A ， TOLANEY S M ， et al . Sacituzumab govitecan in metastatic triple-negative breast cancer [J ] . N Engl J Med ， 2021 ， 384 （ 16 ）： 1529 - 1541 .

BARDIA A ， RUGO H S ， TOLANEY S M ， et al . Final results from the randomized phase Ⅲ ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression [J ] . J Clin Oncol ， 2024 ， 42 （ 15 ）： 1738 - 1744 .

YIN Y M ， FAN Y ， OUYANG Q C ， et al . Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer：a randomized phase 3 trial [J ] . Nat Med ， 2025 ， 31 （ 6 ）： 1969 - 1975 .

EISENHAUER E A ， THERASSE P ， BOGAERTS J ， et al . New response evaluation criteria in solid tumours：revised RECIST guideline：version 1.1 [J ] . Eur J Cancer ， 2009 ， 45 （ 2 ）： 228 - 247 .

HSU J Y ， CHANG C J ， CHENG J S . Survival，treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer [J ] . Sci Rep ， 2022 ， 12 （ 1 ）： 729 .

刘国恩 . 中国药物经济学评价指南2020 [M ] . 北京：中国市场出版社， 2020 ： 27 - 46 .

周颖玉，吴群红 . 经济学理论视角下的健康贴现率研究 [J ] . 中国卫生经济， 2023 ， 42 （ 1 ）： 1 - 3 .

中国抗癌协会乳腺癌专业委员会，中国抗癌协会国际医疗交流分会，中国医师协会肿瘤医师分会乳腺癌学组 . 中国晚期三阴性乳腺癌临床诊疗指南： 2024版 [J ] . 中华肿瘤杂志， 2024 ， 46 （ 6 ）： 471 - 480 .

CAI H F ， HUANG L S ， ZHENG Z W . Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer：a cost-effectiveness analysis [J ] . Front Public Health ， 2024 ， 12 ： 1421826 .

石丰豪，商叶，芮明军，等 . R语言survHE程序包在卫生经济学评价中的应用 [J ] . 中国卫生经济， 2020 ， 39 （ 9 ）： 9 - 14 .

PERNAS S ， IM S A ， HATTORI M ， et al . Datopotamab deruxtecan（Dato-DXd）vs chemotherapy（CT）in previously treated inoperable or metastatic hormone receptor-positive，HER2-negative（HR+/HER2－）breast cancer（BC）：patient-reported outcomes（PROs）from the TROPION-Breast01 study [J ] . J Clin Oncol ， 2024 ， 42 （ Suppl. 16 ）： 1006 .

WU B ， MA F . Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer [J ] . Ther Adv Med Oncol ， 2020 ， 12 ： 1758835920916000 .

WANG L ， LIU L L ， ZHANG Z ， et al . Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for patients with metastatic triple-negative breast cancer in China [J ] . Clin Breast Cancer ， 2024 ， 24 （ 7 ）： e545 - e553 .e6.

ZHU Y W ， LIU K ， WANG M ， et al . Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer：a cost-effectiveness analysis [J ] . Breast ， 2022 ， 66 ： 191 - 198 .

LI J B ， LIN Z C ， WONG M C S ， et al . A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society [J ] . BMC Med ， 2022 ， 20 （ 1 ）： 320 .

ZHAN M ， HUANG Z J ， XU T ， et al . Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04 [J ] . Front Public Health ， 2023 ， 11 ： 1049947 .

ZOU H M ， LAI Y F ， CHEN X W ， et al . Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma [J ] . Therap Adv Gastroenterol ， 2025 ， 18 ： 17562848241310314 .

SHI G H ， PARK S H ， REN H Y ， et al . Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China [J ] . J Med Econ ， 2018 ， 21 （ 12 ）： 1150 - 1158 .

GAN Y N ， SHI F H ， ZHU H ， et al . Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and societal perspectives [J ] . Front Pharmacol ， 2024 ， 15 ： 1256992 .

YUE X M ， LI Y X ， WU J H ， et al . Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China [J ] . Value Health Reg Issues ， 2021 ， 24 ： 1 - 5 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

Analysis of cost-effectiveness of amivantamab combined with chemotherapy in the treatment of EGFR-mutated advanced non-small cell lung cancer

Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty

Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

Cost-effectiveness analysis of tislelizumab combined with chemotherapy as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Related Author

ZHAN Shaoqing

CHEN Xia

ZHOU Jiaqi

LIU Xiaoya

WANG Xianying

LIANG Miao

LIU Yang

LIU Zheng

Related Institution

Dept. of Pharmacy， Nantong First People’s Hospital

Dept. of Pharmacy， Hebei Medical University Third Hospital

Dept. of Pharmacy， West China Second Hospital， Sichuan University

Evidence-based Medicine Center， West China Hospital， Sichuan University

Molecular Translational Medicine Laboratory， Translational Medicine Center， Sichuan University

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰